Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

<p><strong>Brief summary:</strong> In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance.</p> <p><strong>Background:</strong> Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-...

Full description

Bibliographic Details
Main Authors: Luvira, V, Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Siripoon, T, Ngamprasertchai, T, Almeida, PJ, Ekkapongpisit, M, Cruz, C, Callery, JJ, Singh, S, Tuntipaiboontana, R, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Keayarsa, S, Madmanee, W, Aguiar, RS, Santos, FM, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Imwong, M, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Other Authors: PLATCOV Collaborative Group
Format: Journal article
Language:English
Published: BioMed Central 2024

Similar Items